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ntithrombin Therapy for
lective Percutaneous
oronary Intervention
hich Agent to Use? Does It Matter?*
orin J. Brener, MD
rooklyn, New York
he notion that antithrombin therapy is needed in patients
ndergoing percutaneous coronary intervention (PCI)
volved empirically from the understanding of the patho-
hysiology of atherosclerosis (1,2) and the mechanisms
nvolved in PCI, particularly with respect to arterial wall
issection and the thrombus formation that can follow (3).
See page 1083
nfractionated heparin (UFH) has been the traditional
ntithrombin agent during PCI, despite little evidence to
upport the need and the intensity of anticoagulation
esired for optimal results (4). In fact, in an analysis of 4
ecent studies of PCI, there was no relationship between the
ntensity (measured with the activated clotting time [ACT])
f anticoagulation with UFH and the incidence of ischemic
omplications (5). As expected, higher ACT was associated
ith a small increase in, predominantly, minor bleeding up
o 365 s, and higher total doses of UFH were also associated
ith more bleeding. Among more than 8,000 patients with
high rate of treatment with thienopyridines and glyco-
rotein IIb/IIIa inhibitors (GPIs) and almost universal
tenting, there was no evidence of a lower threshold for
nticoagulation below which ischemic events were in-
reased. Moreover, the median ACT did not differ among
atients with or without ischemic or hemorrhagic events in
PCI trials. Some even suggested that only a minimal dose
f UFH is needed when adequate antiplatelet therapy is
rovided (6).
In this issue of JACC: Cardiovascular Interventions, Mon-
alescot et al. (7) provide the 1-year outcome of the
TEEPLE (Safety and Efficacy of Enoxaparin in PCI
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.b
From the New York Methodist Hospital, Division of Cardiology, Brooklyn,
ew York.atients, an International Randomized Evaluation) trial,
nitially published in 2006 (8). Elective PCI patients, nearly
ll pre-treated with clopidogrel and not previously treated
ith an antithrombin agent, were randomized to receive a
ingle IV dose of enoxaparin 0.50 or 0.75 mg/kg (without
eight restriction) or UFH with ACT adjustment to 300 to
50 s in the absence of GPI and 200 to 300 s in the presence
f GPI (40% of patients). The primary end point, assessed
or noninferiority, was noncoronary artery bypass graft
urgery major or minor bleeding within 48 h of PCI
Table 1). Compared with UFH, bleeding was reduced by
noxaparin from 8.5% to 6.5% (0.75 mg/kg dose, p  0.05)
nd 5.9% (0.50 mg/kg dose, p  0.01), respectively.
ajor bleeding occurred in 2.8%, 1.2% (p  0.007), and
.2% (p  0.004), respectively. The main category in
hich a reduction was noted was the 3 g/dl decrease in
emoglobin. There was no significant difference in the
ncidence of minor bleeding or ischemic events among the
roups. Of note is that using other scales of bleeding, such
s the Thrombolysis In Myocardial Infarction (TIMI) flow
rade (9) and the GUSTO (Global Utilization of Strep-
okinase and TPA for Occluded Arteries) (10), did not
eveal any significant differences in the primary end point
mong the groups. There were 5 events of TIMI major
leeding in each of the groups. Only one-fifth of UFH
atients were in the pre-specified range of 0.5 to 1.8 IU/ml
f anti-Xa activity, compared with 79% and 92% of the
noxaparin groups, respectively. Notwithstanding the ac-
nowledged limitations of insufficient power for the mor-
ality end point, the need to re-consent patients for un-
lanned 1-year follow-up, and the substantial loss of
atients for follow-up, at 1 year the cumulative rates of
ll-cause mortality were 1.9%, 2.2%, and 2.3%, for enox-
parin 0.50 mg/kg, enoxaparin 0.75 mg/kg, and UFH,
espectively (pNS). Echoing many recent publications on
he predictors of 1-year mortality (11–13), the authors
ound that having periprocedural bleeding or an ischemic
vent increases the odds of subsequent death by a factor of
.0 and 1.7, respectively.
The STEEPLE trial also provided a lesson in trial
onduct. Early termination of the 0.5-mg/kg dose allocation
ecause of a higher number of deaths resulted in only a
mall discrepancy in the overall enrollment, because the trial
as completed anyhow 1 month after the decision to stop
nrollment in the 0.50-mg/kg arm. Furthermore, the pre-
iminary analysis was not confirmed at 1 year, when the rate
f death was numerically the lowest in the group terminated
arly.
The American College of Cardiology recommends the
se of UFH during PCI, with the dose adjusted for ACT
Class I, Level of Evidence: C), or enoxaparin (Class IIa,
evel of Evidence: B) (14). The former is unpredictable
ith respect to its anticoagulant effect, is more likely to be
ound by circulating proteins, and incites a vascular re-
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1093ponse that promotes platelet adhesion and aggregation by
iberating vonWillebrand factor from the endothelium. Yet,
t can be easily reversed and offers to many practitioners the
omfort of familiarity and measurement of effect. Enoxapa-
in is extremely predictable in its effect (15), does not
equire monitoring or adjustments (particularly for single
ose), and is less conducive to platelet adhesion and
ggregation. Its main disadvantage is the inability to
everse it quickly and completely. Higher costs have also
imited its penetration for this indication in the U.S.
Does the follow-up information from the STEEPLE
rial modify this balance? Is it a reason to adjust the
ecommendation for PCI anticoagulation? Probably not!
he population studied was very low-risk, and the majority
f major bleeding events in each group were related to an
symptomatic decrease in hemoglobin. The more important
ontribution of the study lies in the confirmation of the
ignificance of periprocedural bleeding as an important
redictor of 1-year mortality. In that respect, this report
oins others in urging all of us to make every effort to lower
he rate of periprocedural significant bleeding by using
nticoagulation judiciously and, potentially, altering the
ccess site in patients at high risk for bleeding. Other
lternatives to UFH and enoxaparin, such as the direct
hrombin inhibitor bivalirudin (16) (Class IIa, Level of
vidence: B) and the synthetic factor Xa inhibitor fondapa-
inux (17), should also be considered as valuable tools for
educing PCI-related bleeding. The former has been shown
o reduce major bleeding regardless of the scale used for its
Table 1. Definitions of Bleeding in the STEEPLE Trial
Major bleeding*
Fatal bleeding
Retroperitoneal, intracranial, or intraocular bleeding
Bleeding that causes hemodynamic compromise requiring speciﬁc treatment
Bleeding that requires intervention (surgical or endoscopic) or decompression
of a closed space to stop or control the event
Clinically overt bleeding, requiring any transfusion of 1 U of packed red cells
or whole blood
Clinically overt bleeding, causing a decrease in hemoglobin of 3 g/dl (or, if
hemoglobin level not available, a decrease in hematocrit of 10%)
Minor bleeding†
Gross hematuria not associated with trauma (e.g., from instrumentation)
Epistaxis that is prolonged, repeated, or requires plugging or intervention
Gastrointestinal hemorrhage
Hemoptysis
Subconjunctival hemorrhage
Hematoma 5 cm or leading to prolonged or new hospital stay
Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dl
Uncontrolled bleeding requiring protamine sulfate administration
*Major bleedingwas defined as bleeding thatmet at least 1 of the criteria listed.†Minor bleeding
was defined as bleeding that did not meet any of the criteria for major bleeding and that met at
least 1 of the criteria forminor bleeding. Reproduced,with permission, fromMontalescot et al. (8).ssessment and has no stimulatory effect on platelets.From this and other reports, we can conclude that elective
CI can be conducted with very few serious ischemic and
emorrhagic complications, regardless of the antithrombin
gent used. Enoxaparin is, certainly, an acceptable alterna-
ive to UFH or bivalirudin, and physicians should acquire
he same level of familiarity with its use as they have with
he time-honored, insufficiently researched, and unpredict-
ble precursor, unfractionated heparin.
It is not how we thin the blood that counts; it is how
uch of it we lose that predicts outcome.
eprint requests and correspondence: Dr. Sorin J. Brener, New
ork Methodist Hospital, Cardiology, 506 6th Street, Brooklyn,
ew York 11215. E-mail: sjb9005@nyp.org.
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